Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.71 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803582 | 1.00 | ADRB2 (0.71) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL1180240 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL1796166 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Acetic Acid SCHEMBL1801841 | 0.93 | ADRB2 (0.67) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Acetic Acid SCHEMBL1803737 | 0.93 | ADRB2 (0.67) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL14291930 | 0.88 | ADRB2 (0.75) | ADRB2ADRB1DRD3 | |
| SCHEMBL13754327 | 0.84 | ADRB2 (0.66) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL13711689 | 0.84 | ADRB2 (0.54) | ADRB2ADRB1DRD3 | |
| SCHEMBL14027825 | 0.83 | ADRB2 (1.00) | ADRB2ADRB1DRD3 | |
| SCHEMBL14382684 | 0.83 | ADRB2 (1.00) | ADRB2ADRB1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074816-B | Heterocyclic derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-107108562-B | With β2ReceptorsNitrogen-containing heterocyclic ring derivative with agonistic and M receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-9757383-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-09-12 | — | — | US | disclosed |
| CN-107074816-A | A kind of Hete rocyclic derivatives and preparation method thereof and in purposes pharmaceutically | 四川海思科制药有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9549934-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-01-24 | — | — | US | disclosed |
| WO-2016180349-A1 | BIPHENYL DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREFOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180348-A1 | NITROGEN-CONTAINING SPIRO-HETEROCYCLIC DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| WO-2016155573-A1 | HETEROCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2016-10-06 | — | — | WO | disclosed |
| US-20160200718-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-07-14 | — | — | US | disclosed |
| EP-2776425-B1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2016-06-01 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2008104790-A1 | SALTS OF A SELECTIVE BETA-2 ANDRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD3 422/4885 |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885DRD3 418/4885 |
| US-20160200718-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | ADRB2 1/4885ADRB1 5/4885DRD3 102/4885 |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885DRD3 576/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | ADRB2 218/4885ADRB1 199/4885DRD3 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.